English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 15 August 2017, 19:00 HKT/SGT
Share:
    

Source: Alset International Limited
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances

SINGAPORE, Aug 15, 2017 - (ACN Newswire) - Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.

3F (Functional Fragrance Formulation) is a suite of functional fragrances being developed. The first product, 3F Mosquito, is made of specialised oils sourced from botanicals which mosquitoes avoid. 3F Mosquito was designed with an objective to identify, then create a suitable formula that was pleasant, yet excels in providing layers of protection against mosquitoes.

Daryl Thompson, Global BioLife Director of Scientific Initiatives, leads the 3F research. "The specialised oils in 3F Mosquito are scientifically proven to affect a mosquito's receptors, essentially making the mosquito blind to your presence," says Thompson.

In addition to 3F Mosquito, Global BioLife and Chemia are developing fragrances as additives for use in laundry detergents, shampoos and lotions, providing additional layers of protection against mosquitoes, and developing advanced coatings for industrial and medical applications.

"Biomedical science has become increasingly vital. Global BioLife is taking steps toward providing solutions to issues that have plagued the biomedical field for decades. This working collaboration marks a first steps in actively changing the game of healthcare," said Chan Heng Fai, SeD Executive Chairman and Chief Executive Officer, and a Global BioLife Director.

Global BioLife is an 80%-held subsidiary of SeD wholly-owned Global BioMedical Inc. The remaining shareholding in Global BioLife is held by Thompson's GRDG Sciences LLC and Australia Securities Exchange-listed Holista CollTech Limited, in equal proportions of 10% each.

About Chemia Corporation
Chemia Corporation provides high quality, cost effective fragrances to the manufacturers of personal care, household and industrial & institutional products. Thomas A. Meyer is the Vice-President of Innovation and Sustainability. For further information, please visit www.chemiacorp.com.

About GRDG Sciences LLC
GRDG Sciences LLC is a natural products discovery drug research company incorporated in Florida, USA. The Company was set up by natural products scientist Daryl Thompson. Thompson is a biochemist, nominated for the Nobel Prize in 2015 and 2016 for his research in pandemic technology.

About Holista CollTech Ltd
Holista CollTech is incorporated in Australia and listed on the Australian Securities Exchange. A research-driven biotechnology company, Holista focuses on research and development of product in the natural products space. Founder and Chief Executive Officer Dr Rajen Manicka holds a PhD in Holistic Medicine and a Masters of Business Administration. For further information, please visit www.holistaco.com.

About Singapore eDevelopment Ltd

Singapore eDevelopment Ltd (SeD) was incorporated on 9 Sept 2009, and listed by SGX Catalist (SGX:SGE) in July 2010. SeD is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg.

Issued for the Company:
WeR1 Consultants Pte Ltd
Ian Lau
Tel : +65 6737 4844
Email: [email protected]


Topic: General Announcement
Sectors: Healthcare & Pharm, Funds & Equities, Cosmetics & Spec.Chem
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Alset International Limited Releated News
Oct 5, 2020 15:25 HKT/SGT
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc.
Sept 18, 2020 17:00 HKT/SGT
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance
July 31, 2020 15:00 HKT/SGT
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development
June 24, 2020 14:00 HKT/SGT
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance
June 17, 2020 18:00 HKT/SGT
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
More news >>
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575